GoodRx Holdings, Inc. (NASDAQ:GDRX) insider Bansi Nagji sold 29,788 shares of the business’s stock in a transaction that occurred on Thursday, September 16th. The stock was sold at an average price of $45.03, for a total transaction of $1,341,353.64. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Shares of GDRX stock traded up $1.64 on Thursday, hitting $45.93. The stock had a trading volume of 1,883,759 shares, compared to its average volume of 1,992,331. GoodRx Holdings, Inc. has a 52-week low of $26.66 and a 52-week high of $64.22. The firm has a market capitalization of $18.17 billion and a price-to-earnings ratio of -52.19. The company has a debt-to-equity ratio of 0.80, a quick ratio of 16.43 and a current ratio of 16.43. The stock’s 50 day moving average is $35.13 and its 200-day moving average is $36.59.
GoodRx (NASDAQ:GDRX) last released its quarterly earnings results on Thursday, August 12th. The company reported $0.08 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.01 by $0.07. GoodRx had a negative return on equity of 39.62% and a negative net margin of 50.01%. The business had revenue of $176.64 million for the quarter, compared to analysts’ expectations of $174.15 million. Equities analysts expect that GoodRx Holdings, Inc. will post 0.04 earnings per share for the current year.
Several brokerages have issued reports on GDRX. Morgan Stanley raised their price objective on GoodRx from $36.00 to $38.00 and gave the stock an “equal weight” rating in a report on Friday, July 2nd. Raymond James upgraded GoodRx from a “market perform” rating to an “outperform” rating and set a $45.00 price objective for the company in a research note on Friday, August 13th. Cowen lowered their target price on shares of GoodRx from $44.00 to $42.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 24th. Zacks Investment Research cut shares of GoodRx from a “hold” rating to a “sell” rating in a research note on Wednesday, August 18th. Finally, Credit Suisse Group lifted their price objective on shares of GoodRx from $45.00 to $52.00 and gave the company an “outperform” rating in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $49.06.
GoodRx Company Profile
GoodRx Holdings, Inc, through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.
Featured Article: Stock Symbol
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.